Nyxoah Initiates Succession of Olivier Taelman to Accelerate in the United States
Nyxoah announced on Thursday the launch of a succession process for its CEO position. Olivier Taelman, who has led the company for seven years, is stepping down to make way for an American CEO to accelerate the commercialization of the Genio system in the U.S. market.
Olivier Taelman is stepping down as CEO after transitioning Nyxoah from a preclinical stage to a global commercial platform. Under his leadership, the company achieved CE marking in Europe in 2019 and FDA approval in August 2025 for the Genio system, a wireless and battery-free hypoglossal neurostimulation treatment for obstructive sleep apnea. Nyxoah also completed two initial public offerings: on Euronext Brussels in September 2020 and on Nasdaq in July 2021. Taelman will continue to lead the company's daily operations during the transition period to ensure a successful handover and transition to the new CEO.
Commercial Acceleration in the United States
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The board of directors has formally initiated a search to identify a new CEO based in the United States. This transition is in response to the company's desire to accelerate its commercial traction in the American market, a critical market for Nyxoah's future growth. Chairman Robert Taub emphasized that the combination of enhanced financial resources, accelerating commercial dynamics in the U.S., and a leadership structure oriented towards the United States would position Nyxoah for its next growth phase in the rapidly expanding obstructive sleep apnea market.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 9,2 millions d'euros
Quarterly revenue: 9,2 millions d'euros
Revenue growth: 366,5 %
Guidance from the release
Bien que nous soyons déçus d'ajuster nos prévisions de chiffre d'affaires
Risks mentioned
Ajustement à la baisse des prévisions de chiffre d'affaires (de 36-40 M€ à 33-35 M€)
Trajectoire de croissance inférieure aux attentes pour l'exercice 2026
Dépendance à la ramp-up des États-Unis reflétant les cycles historiques d'une nouvelle technologie
Opportunities identified
Supplément PMA soumis à la FDA pour étendre l'indication américaine aux patients atteints de collapsus concentrique complet
Croissance séquentielle de 29 % du chiffre d'affaires aux États-Unis au T3 2026
Expansion du nombre de chirurgiens formés (342 cumulés) et comptes activés (233 à fort volume) aux États-Unis
Outlook / guidance
Expected revenue: 34 millions d'euros
Management commentary: The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
